First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Celldex Therapeutics: the story is balanced — Barzolvolimab Phase 2b data readouts in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU)…
★ Analysts see FY2027 revenue reaching $11M — +400% growth in a single year.
What Moves the Stock
1Barzolvolimab Phase 2b data readouts in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) - primary endpoints on itch severity and urticaria activity scores
2FDA regulatory pathway clarity and potential breakthrough therapy designation for barzolvolimab in urticaria indications
3Clinical trial initiation announcements for barzolvolimab expansion into additional mast cell-driven diseases (hereditary alpha tryptasemia, systemic mastocytosis)
4Cash runway updates and equity financing announcements - dilution concerns vs. funding adequacy
5Strategic partnership or licensing deals that validate platform technology and provide non-dilutive capital
6No current commercial revenue - pre-revenue clinical-stage company
7Potential future revenue from barzolvolimab in chronic urticaria (estimated peak sales $1-2B+ if approved)
8Potential milestone payments and royalties from future partnerships or out-licensing deals
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (barzolvolimab revenues…
Watch on earnings: Barzolvolimab Phase 2b trial enrollment completion and data readout timing (expected 2026-2027), Quarterly cash burn rate and total cash/equivalents balance - runway through key milestones, FDA feedback on regulatory pathway and potential accelerated approval eligibility.
One Sentence Summary:
Celldex Therapeutics: the story is balanced — barzolvolimab phase 2b data readouts in chronic spontaneous urticaria (csu) and chronic inducible urticaria (cindu) - primary endpoints.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.